A comprehensive rubric-based ranking of all known Parkinson's disease therapeutic approaches using a 7-dimension scoring framework. [1]
Comprehensive rubric-based ranking of all known Parkinson's disease therapeutic approaches using a 7-dimension scoring framework.
Each approach is scored 0-10 on seven key dimensions: [2]
| Dimension | Description | [3]
|-----------|-------------| [4]
| Mechanistic Clarity | Do we understand HOW this works at molecular level? | [5]
| Clinical Evidence | Phase 1/2/3 trial data, epidemiological support | [6]
| Delivery Feasibility | Can we get this to the brain at therapeutic doses? | [7]
| Safety Profile | Side effects, long-term toxicity, surgical risks | [8]
| Combinability | Can this pair with other approaches synergistically? | [9]
| Timeline to Impact | How soon could patients benefit? | [10]
| Addresses Root Cause | Does this fix upstream pathology or just symptoms? | [11]
Max Score: 70 points [9:1]
| Rank | Approach | MC | CE | DF | SP | CB | TI | AC | Total |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Levodopa/Carbidopa | 10 | 10 | 8 | 7 | 8 | 10 | 5 | 58 |
| 2 | Exercise/Lifestyle interventions | 8 | 8 | 10 | 10 | 9 | 9 | 6 | 60 |
| 3 | MAO-B inhibitors (rasagiline, safinamide) | 9 | 9 | 9 | 8 | 7 | 9 | 5 | 56 |
| 4 | GLP-1 receptor agonists | 8 | 8 | 8 | 8 | 9 | 8 | 7 | 56 |
| 5 | Alpha-synuclein antibodies (prasinezumab) | 8 | 8 | 7 | 7 | 8 | 8 | 9 | 55 |
| 6 | Deep Brain Stimulation | 9 | 9 | 8 | 7 | 7 | 8 | 5 | 53 |
| 7 | LRRK2 inhibitors (dNL-1, BIIB122) | 8 | 7 | 7 | 8 | 8 | 6 | 9 | 53 |
| 8 | Dopamine agonists | 9 | 9 | 8 | 6 | 7 | 9 | 5 | 53 |
| Rank | Approach | MC | CE | DF | SP | CB | TI | AC | Total |
|---|---|---|---|---|---|---|---|---|---|
| 9 | GBA chaperones (ambroxol) | 7 | 6 | 7 | 8 | 7 | 6 | 8 | 49 |
| 10 | Gene therapy (AAV-GAD, AAV-AADC) | 8 | 6 | 6 | 7 | 6 | 6 | 9 | 48 |
| 11 | COMT inhibitors (opicapone) | 9 | 8 | 8 | 7 | 7 | 8 | 5 | 52 |
| 12 | Alpha-synuclein aggregation inhibitors | 7 | 5 | 7 | 7 | 8 | 5 | 8 | 47 |
| 13 | Tau-targeted therapies | 7 | 5 | 7 | 7 | 7 | 5 | 8 | 46 |
| 14 | Apomorphine (pump/injection) | 8 | 7 | 7 | 6 | 6 | 8 | 5 | 47 |
| 15 | Mitochondrial therapies (coQ10, NAD+) | 7 | 5 | 7 | 8 | 7 | 6 | 8 | 48 |
| 16 | Senolytics (dasatinib+quercetin) | 7 | 4 | 6 | 7 | 7 | 5 | 8 | 44 |
| 17 | Neurotrophic factors (GDNF, BDNF) | 7 | 4 | 5 | 6 | 6 | 4 | 9 | 41 |
| Rank | Approach | MC | CE | DF | SP | CB | TI | AC | Total |
|---|---|---|---|---|---|---|---|---|---|
| 18 | Cell replacement therapy | 5 | 3 | 4 | 5 | 4 | 3 | 8 | 32 |
| 19 | Alpha-synuclein ASOs | 7 | 4 | 6 | 6 | 6 | 4 | 8 | 41 |
| 20 | Gut microbiome modulation | 5 | 3 | 6 | 7 | 6 | 4 | 7 | 38 |
| 21 | Focused ultrasound | 6 | 4 | 7 | 7 | 5 | 5 | 6 | 40 |
| 22 | CRISPR gene editing | 4 | 2 | 3 | 4 | 4 | 3 | 9 | 29 |
Mechanistic Clarity (8/10): Exercise, diet, and sleep have well-documented mechanisms including BDNF induction, neuroinflammation reduction, alpha-synuclein clearance via glymphatic system.
Clinical Evidence (8/10): Multiple studies show 35-50% risk reduction with regular exercise; FINGER trial demonstrated cognitive benefits in prodromal PD.
Delivery Feasibility (10/10): No drug delivery needed; accessible to all patients.
Safety Profile (10/10): No adverse effects; only positive side benefits including cardiovascular health.
Combinability (9/10): Can combine with any pharmacological approach.
Timeline to Impact (9/10): Immediate implementation possible.
Addresses Root Cause (6/10): Addresses multiple risk factors but doesn't reverse established dopaminergic loss.
Mechanistic Clarity (10/10): Complete understanding of dopamine replacement mechanism; well-characterized pharmacokinetics.
Clinical Evidence (10/10): Gold standard since 1960s; extensive Phase 4 data across millions of patients.
Delivery Feasibility (8/10): Oral delivery; some formulations require intestinal infusion for advanced disease.
Safety Profile (7/10): Motor complications (dyskinesias), hallucinations, impulse control disorders.
Combinability (8/10): Combines well with COMT inhibitors, MAO-B inhibitors, dopamine agonists.
Timeline to Impact (10/10): Immediate symptomatic relief.
Addresses Root Cause (5/10): Pure symptomatic treatment; does not slow disease progression.
Mechanistic Clarity (9/10): Well-characterized mechanism of dopamine metabolism inhibition.
Clinical Evidence (9/10): TEMPO, ADAGIO trials showed symptomatic benefit; potential disease-modifying effects debated.
Delivery Feasibility (9/10): Oral once-daily dosing; good brain penetration.
Safety Profile (8/10): Generally well-tolerated; selegiline has dietary restrictions at high doses.
Combinability (7/10): Used as adjunct to levodopa; limited combination with other MAO-B agents.
Timeline to Impact (9/10): Approved and accessible; benefits seen within weeks.
Addresses Root Cause (5/10): Symptomatic relief; disease-modifying potential uncertain.
Mechanistic Clarity (8/10): Multiple mechanisms including neuroinflammation reduction, neurotrophic effects, mitochondrial protection.
Clinical Evidence (7/10): Phase 2 trials (EXERD, NS-089) ongoing; observational data in diabetes patients suggests neuroprotection.
Delivery Feasibility (8/10): Weekly subcutaneous injection; demonstrated brain penetration.
Safety Profile (8/10): Well-established safety from diabetes indications; GI side effects common.
Combinability (9/10): Excellent combinatorial potential with most other approaches.
Timeline to Impact (7/10): Could be repurposed within 2-3 years if trials positive.
Addresses Root Cause (7/10): Targets neuroinflammation and metabolic dysfunction—key upstream factors in PD pathogenesis.
Mechanistic Clarity (9/10): Direct dopamine receptor stimulation well-characterized.
Clinical Evidence (9/10): Extensive use in clinical practice; proven symptomatic benefit.
Delivery Feasibility (8/10): Oral and transdermal options available.
Safety Profile (6/10): Impulse control disorders, sleep attacks, leg edema; ergot derivatives have cardiac valve fibrosis risk.
Combinability (7/10): Used with levodopa; reduces motor complications vs levodopa monotherapy.
Timeline to Impact (9/10): Approved and accessible.
Addresses Root Cause (5/10): Pure symptomatic treatment.
Mechanistic Clarity (9/10): Well-understood modulation of basal ganglia circuits.
Clinical Evidence (9/10): FDA-approved; extensive data from EARLYSTIM and other trials.
Delivery Feasibility (8/10): Surgical implantation; requires specialized center.
Safety Profile (7/10): Surgical risks (infection, hemorrhage), hardware complications, speech/cognitive side effects.
Combinability (7/10): Works with medication adjustments; cannot combine with some therapies.
Timeline to Impact (8/10): Benefits seen soon after implantation and programming.
Addresses Root Cause (5/10): Circuit modulation; does not modify disease progression.
Mechanistic Clarity (8/10): Targets extracellular alpha-synuclein aggregation and spread.
Clinical Evidence (7/10): PASADENA, SPARK trials showed slowing of motor progression; biomarker effects observed.
Delivery Feasibility (7/10): IV infusion monthly; crosses BBB via endogenous transport.
Safety Profile (7/10): Generally well-tolerated; infusion-related reactions possible.
Combinability (8/10): Being tested with LRRK2 inhibitors; potential combinations.
Timeline to Impact (7/10): Could receive approval within 2-3 years.
Addresses Root Cause (9/10): Targets key pathological protein in PD pathogenesis.
Mechanistic Clarity (8/10): Targets LRRK2 kinase hyperactivity implicated in familial and sporadic PD.
Clinical Evidence (6/10): Phase 1/2 trials ongoing; LRRK2 mutation carriers show target engagement.
Delivery Feasibility (7/10): Oral small molecule; good brain penetration expected.
Safety Profile (8/10): Safety data from Phase 1 encouraging; lung/kidney monitoring required.
Combinability (8/10): Being tested with alpha-synuclein antibodies.
Timeline to Impact (6/10): 5+ years to potential approval.
Addresses Root Cause (9/10): Targets LRRK2 pathway implicated in lysosomal dysfunction and protein aggregation.
Mechanistic Clarity (7/10): Increases glucocerebrosidase activity, reducing alpha-synuclein aggregation risk.
Clinical Evidence (5/10): Phase 2 trial showed safety and CSF biomarker changes; larger trials needed.
Delivery Feasibility (7/10): Oral delivery; requires high doses for brain penetration.
Safety Profile (8/10): Well-tolerated; long-term safety data from respiratory indications.
Combinability (7/10): Potential combination with other disease-modifying approaches.
Timeline to Impact (6/10): 5+ years; repurposing path possible.
Addresses Root Cause (8/10): Targets GBA-associated lysosomal dysfunction—a key PD risk factor.
Mechanistic Clarity (8/10): Direct delivery of genes encoding dopamine synthesis enzymes or GAD.
Clinical Evidence (5/10): Phase 2 trials showed motor benefits; durability questions remain.
Delivery Feasibility (6/10): Surgical delivery to striatum; one-time treatment.
Safety Profile (7/10): Surgical risks; potential immune response to viral vector.
Combinability (6/10): Limited combinatorial options due to surgical nature.
Timeline to Impact (5/10): Approved in some regions; broader adoption requires more data.
Addresses Root Cause (9/10): Addresses dopamine deficiency at genetic level; potential for long-term benefit.
Lifestyle ranks highest due to safety, accessibility, and evidence base—but doesn't treat established disease.
Levodopa remains gold standard for symptomatic relief despite being purely symptomatic.
Disease-modifying therapies (alpha-synuclein antibodies, LRRK2 inhibitors) score high on "addresses root cause" but lag in clinical evidence.
GLP-1 agonists represent a promising bridge—repurposable, good safety, multi-target mechanism.
Combination approaches will likely dominate future PD treatment: symptomatic + disease-modifying + lifestyle.
| Drug | Company | Phase | Status | Key Data |
|---|---|---|---|---|
| BIIB122 | Biogen/Denali | Phase 2b (LUMINATE) | Recruiting | 2025-2026 trials in LRRK2-PD and sporadic PD [7:1] |
| DNL151 | Denali/AbbVie | Phase 2 | Active | Improved safety over first-gen inhibitors [5:1] |
Updated Scoring Rationale: LRRK2 inhibitors have advanced significantly with Phase 2b trials. The LUMINATE program (NCT05848079) is evaluating BIIB122 in both LRRK2-associated and sporadic PD, representing the most comprehensive LRRK2 inhibitor trial to date.
| Drug | Company | Phase | Key Finding | Score Impact |
|---|---|---|---|---|
| Prasinezumab | Roche/Prothelia | Phase 2b | Motor progression slowdown at 2 years; biomarker correlation | 54 (up from 53) |
| Cinomerersen | Biogen/Ionis | Phase 2 | Ongoing; targeting intracellular α-syn | Pending |
| UCB7853 | UCB | Phase 1-2 | Dose-selection ongoing | Pending |
The SPARK trial 2-year results demonstrated sustained motor progression slowing, with biomarker data supporting disease modification [6:1].
| Approach | Company | Phase | Mechanism | Status |
|---|---|---|---|---|
| Ambroxol | Multiple | Phase 2-3 | GCase chaperone | Phase 3 trials initiated [8:1] |
| AAV-GBA | Prevail/Eli Lilly | Phase 1-2 | Gene replacement | Positive Phase 1 results [12] |
| GZ/SAR402671 | Sanofi | Phase 2 | Small molecule | Discontinued; safety concerns |
| Approach | Company | Phase | Long-term Data | Score Impact |
|---|---|---|---|---|
| AAV-AADC | Voyager/Neurocrine | Phase 1-2 | 5-year durability confirmed | 48 (up from 46) |
| AAV-GAD | AbbVie | Phase 2 | 5+ year follow-up | Sustained benefit |
| AAV-NTN1 | BrainNeuro | Phase 1 | Ongoing | Early signals positive |
AAV-AADC gene therapy demonstrated sustained motor benefits at 5 years, addressing prior durability concerns [9:2].
| Approach | Mechanism | Delivery | Clinical Stage | Key Advantage |
|---|---|---|---|---|
| BIIB122 | Kinase inhibitor | Oral | Phase 2b | Brain-penetrant, selective |
| DNL151 | Kinase inhibitor | Oral | Phase 2 | Dose-optimized |
| LRRK2-ASO | Gene knockdown | Intrathecal | Preclinical | Mutation-specific |
| Approach | Mechanism | Delivery | Clinical Stage | Key Advantage |
|---|---|---|---|---|
| Ambroxol | GCase chaperone | Oral | Phase 2-3 | Repurposed, safe |
| AAV-GBA | Gene therapy | Intraparenchymal | Phase 1-2 | One-time treatment |
| Venglustat | GCase modulator | Oral | Phase 2 | Brain-penetrant |
| Approach | Mechanism | Delivery | Clinical Stage | Key Advantage |
|---|---|---|---|---|
| Prasinezumab | Antibody | IV | Phase 2b | Extracellular target |
| Cinomerersen | ASO | Intrathecal | Phase 2 | Intracellular target |
| ACI-35 | Vaccine | IM | Phase 1 | Active immunization |
Targeting the UPS represents a novel disease-modifying approach that addresses protein clearance deficits in PD [11:1]:
| Target | Drug Class | Stage | Mechanism |
|---|---|---|---|
| 19S regulatory particle | Small molecule | Preclinical | Enhance proteasome activity |
| E3 ligases | Modulators | Preclinical | Normalize ubiquitination |
| Autophagy-lysosome | TFEB activators | Phase 1 | Enhance clearance |
The GLP-1 receptor agonist pipeline has expanded significantly:
| Drug | Company | Phase | Status |
|---|---|---|---|
| Semaglutide | Novo Nordisk | Phase 3 (EVOKE/EVOKE+) | Results 2026 |
| Exenatide | Auckland/UCB | Phase 4 | Long-term extension |
| NS-089 | Novo Nordisk | Phase 2 | Ongoing [10:1] |
DBS mechanism of action (2023). 2023. ↩︎
EARLYSTIM trial (2022). 2022. ↩︎
LRRK2 biology in PD (2025). 2025. ↩︎ ↩︎
UBL-UPS enhancement in neurodegenerative disease (2025). 2025. ↩︎ ↩︎